CDMO stocks and market chatter
Social posts are highlighting strong investor interest in select CDMO stocks as high‑relative‑strength plays, while Samsung Biologics marked its 10th anniversary on the Korean exchange and Laurus Labs drew attention for big year‑over‑year EPS growth. ( )
Contract drug makers are back in focus as investors chase companies with rising earnings, expanding factory capacity, and stronger share-price momentum. (samsungbiologics.com) A contract development and manufacturing organization builds medicines for other drug companies, handling process development, testing, and large-scale production instead of selling its own branded drugs. Samsung Biologics said its 2025 revenue reached 4.557 trillion won and operating profit hit 2.069 trillion won as Plants 1 through 4 ran full and Plant 5 started operations in April 2025. (samsungbiologics.com; samsungbiologics.com) Samsung Biologics listed on the Korea Exchange on November 10, 2016, so the 10-year marker falls in November 2026. The company has used that decade to scale Songdo production capacity to 785,000 liters across Plants 1 through 5, and it said total global capacity will reach 845,000 liters after its Rockville, Maryland acquisition closes. (clearygottlieb.com; samsungbiologics.com; pharmasource.global) Laurus Labs is getting the same attention for a different reason: profit growth. The company said January 23 that third-quarter fiscal 2026 revenue rose 26% year over year to 1,778 crore rupees, while profit after tax rose 174% to 252 crore rupees. (lauruslabs.com) For the first nine months of fiscal 2026, Laurus Labs said revenue rose 30% to 5,001 crore rupees, earnings before interest, taxes, depreciation, and amortization more than doubled to 1,303 crore rupees, and net debt to earnings before interest, taxes, depreciation, and amortization improved to 1.2 times. Management said its contract development and manufacturing business grew more than 50% year to date. (lauruslabs.com; finance.yahoo.com) That mix of visible orders, new capacity, and fast earnings growth helps explain the market chatter around “relative strength,” a trading term for stocks outperforming a benchmark or peers over a set period. Laurus Labs shares had doubled over the prior 12 months by late February, while Samsung Biologics was up about 58% over one year in recent market-cap tracking data. (cnbctv18.com; companiesmarketcap.com) The backdrop is a drug industry that increasingly outsources expensive biologics production to specialists with approved plants and room to add volume. Samsung Biologics said Plant 5 added 180,000 liters in April 2025, and Laurus Labs has told investors it is spending heavily to expand manufacturing and niche capabilities. (samsungbiologics.com; quartr.com) There are still differences inside the trade. Samsung Biologics is a pure-play biologics contractor after completing the spin-off of Samsung Bioepis in November 2025, while Laurus Labs still spans generic active ingredients, finished-dose drugs, and contract manufacturing. (samsungbiologics.com; lauruslabs.com) The near-term test is whether fresh capacity turns into more signed work and whether earnings keep compounding at the pace investors now expect. For now, the stocks attracting the loudest attention are the ones showing the clearest numbers. (samsungbiologics.com; lauruslabs.com)
